Protagonist Therapeutics, Inc
PN-477
Countdown
208days
Phase 1 readout · Jan 31, 2027
What's at stake
Phase 1 trial results for PN-477 in its lead indication are due Jan 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“PN-477 (triple-G GLP/GIP/GCG agonist peptide): Phase 1 initiation of PN-477sc and PN-477o anticipated in mid-2026 and Q1 2027, respectively.”